Avalo Therapeutics, Inc.

As of June 30, 2026, Avalo Therapeutics Inc carries a market capitalization of 858.05M, placing it among publicly traded companies globally. Its enterprise value stands at 507.90M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Avalo Therapeutics Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Avalo Therapeutics Inc has 52.90M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7,555.39, and the price-to-book ratio stands at 2.18.

These figures are as of June 30, 2026. The EV/Sales ratio of 9,834.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 507.90M versus a market cap of 858.05M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Avalo Therapeutics Inc maintains a current ratio of 19.31, meaning it holds 19.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Avalo Therapeutics Inc posted a negative return on equity (ROE) of -36.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.50, reflecting losses generated across the asset base. The company generates approximately 1,693.20 in revenue per employee across its workforce of 30.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Avalo Therapeutics Inc recorded 149,676.30 in income tax expense. The company reported a pretax loss of -87.67M and -87.82M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Avalo Therapeutics Inc's stock has declined approximately 51.02% over the past 52 weeks. The 50-day moving average sits at 14.24, while the 200-day moving average is 14.18.

Over the twelve months ended June 30, 2026, Avalo Therapeutics Inc generated 51,642.70 in revenue and converted that into -87.82M in net income, yielding earnings per share of -3.65. EBITDA reached -79.87M, while operating income came in at -79.97M.

As of June 30, 2026, Avalo Therapeutics Inc holds 350.36M in cash and equivalents against 211,822.60 in total debt, resulting in a net debt position of -74.73M. Total book value stands at 392.71M, with working capital of 338.57M providing operational flexibility.

Avalo Therapeutics Inc produced -59.77M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -154,844.07 and net profit margin of -170,055.93 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -43.52, meaning Avalo Therapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Avalo Therapeutics Inc's most recent stock split took place on January 2, 2024 with a 240:1 split ratio.

As of June 30, 2026, Avalo Therapeutics Inc has an Altman Z-Score of 12.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.